Literature DB >> 8973662

Immunological demonstration of protein kinase C mu in murine tissues and various cell lines. Differential recognition of phosphorylated forms and lack of down-regulation upon 12-O-tetradecanoylphorphol-13-acetate treatment of cells.

J Rennecke1, F J Johannes, K H Richter, W Kittstein, F Marks, M Gschwendt.   

Abstract

13 murine tissues and 12 cell lines were tested for the expression of the novel protein kinase C (PKC) isoenzyme mu. Using two different PKC mu antibodies (sc-639 and P26720), PKC mu was detected in all tissues and cells and thus proved to be an ubiquitous PKC isotype. However, in some tissues, PKC mu was recognized only by the antibody P26720 and not by sc-639. Thymus, lung and peripheral blood mononuclear cells expressed the greatest amount of PKC mu. Recognition of PKC mu by the antibody sc-639 was drastically impaired when treating keratinocytes or mouse skin in vivo with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), thus mimicking down-regulation of PKC mu. The lack of a decrease in the PKC mu amount and, thus, the lack of down-regulation could be proved using the antibody P26720. This antibody was able to recognize PKC mu in extracts of untreated as well as TPA-treated tissues or cells. Phosphorylation of proteins in a cell-free system (cell or tissue extracts) in the presence and absence of TPA or other PKC activators and various protein kinase inhibitors indicated that phosphorylation of activated PKC mu caused its reduced interaction with the antibody sc-639. Therefore, this antibody might present a well suited tool for the detection of activated PKC mu in vivo. Moreover, our results clearly show that some antibodies, such as sc-639, might be able to selectively detect non-phosphorylated or phosphorylated forms of a protein, and that such properties of an antibody have to be studied carefully before the latter can be used for reliable quantitative determination of this protein. We consider this information important to avoid misinterpretation of data concerning the immunological quantification of proteins such as PKC mu.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973662     DOI: 10.1111/j.1432-1033.1996.0428r.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Involvement of protein kinase D in Fc gamma-receptor activation of the NADPH oxidase in neutrophils.

Authors:  Jan K Davidson-Moncada; Guillermo Lopez-Lluch; Anthony W Segal; Lodewijk V Dekker
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

2.  A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-{kappa}B activities.

Authors:  Jun Chen; Karthik V Giridhar; Liyong Zhang; Shuping Xu; Q Jane Wang
Journal:  Carcinogenesis       Date:  2011-06-10       Impact factor: 4.944

3.  Protective effect of 4,4'-diaminodiphenylsulfone against paraquat-induced mouse lung injury.

Authors:  Sung Chun Cho; Ji Heon Rhim; Hae Ri Choi; Young Hoon Son; Seok Jin Lee; Kye Yong Song; Sang Chul Park
Journal:  Exp Mol Med       Date:  2011-09-30       Impact factor: 8.718

4.  Angiotensin II-activated protein kinase D mediates acute aldosterone secretion.

Authors:  Brian A Shapiro; Lawrence Olala; Senthil Nathan Arun; Peter M Parker; Mariya V George; Wendy B Bollag
Journal:  Mol Cell Endocrinol       Date:  2009-12-02       Impact factor: 4.102

5.  Protein kinase D links Gq-coupled receptors to cAMP response element-binding protein (CREB)-Ser133 phosphorylation in the heart.

Authors:  Nazira Ozgen; Maria Obreztchikova; Jianfen Guo; Hasnae Elouardighi; Gerald W Dorn; Brenda A Wilson; Susan F Steinberg
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

6.  Structural requirements for localization and activation of protein kinase C mu (PKC mu) at the Golgi compartment.

Authors:  Angelika Hausser; Gisela Link; Linda Bamberg; Annett Burzlaff; Sylke Lutz; Klaus Pfizenmaier; Franz-Josef Johannes
Journal:  J Cell Biol       Date:  2002-01-03       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.